SCYNEXIS (Nasdaq: SCYX) announced inducement equity awards approved April 30, 2026 for a newly hired Vice President. The grants include stock options for 125,000 shares at an exercise price of $0.93 and 20,000 RSUs.
Options vest over four years starting April 13, 2026; RSUs vest in three equal annual installments beginning June 15, 2026. Awards were granted under the company’s 2015 Inducement Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – SCYX
-2.51%
-2.51%Session close to close
In the May 7 session, SCYX declined 2.51%, reflecting a moderate negative market reaction.
This announcement details a standard inducement equity package for a new vice president, including 1...
Analysis
This announcement details a standard inducement equity package for a new vice president, including 125,000 stock options at $0.93 and 20,000 RSUs with multi‑year vesting. It follows larger strategic steps such as the acquisition of SCY-770 and a $40M private placement. Investors may watch future filings on equity plans, the S-3 registering 87,000,000 resale shares, and progress on SCY‑770 and SCY‑247 as more material drivers.
Key Figures
Current share price:$0.9819Inducement option grant:125,000 optionsOption exercise price:$0.93 per share+5 more
8 metrics
Current share price$0.9819Pre-news market context
Inducement option grant125,000 optionsNew VP inducement award
Option exercise price$0.93 per shareClosing price on April 30, 2026
Inducement RSUs20,000 RSUsNew VP inducement award
Vest period options4 years25% at one year, then monthly over 36 months
Vest period RSUs3 yearsThree equal annual installments
Registered resale shares87,000,000 sharesS-3 shelf for private placement purchasers
Shares outstanding79,442,633 sharesAs of April 1, 2026 (S-3 filing)
First participants dosed in Phase 1 IV SCY-247 SAD/MAD trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent fundamentally positive events (asset acquisition, financing, earnings) often saw positive price reactions, with one clinical update showing a mild divergence.
Recent Company History
Over the last few months, SCYNEXIS announced a transformative acquisition of SCY-770, a related sale and licensing deal for up to $196M, and a $40M private placement extending cash runway into mid-2029. A Phase 1 IV SCY-247 trial initiation and 2025 results with $20.6M revenue also supported the story. Those events generally produced positive price reactions, framing today’s inducement awards as a smaller HR-related step following larger strategic moves.
"approved inducement equity awards ... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
restricted stock unitsfinancial
"and restricted stock units (“RSUs”) covering 20,000 shares of the Company’s common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vestingfinancial
"the shares underlying the option vesting on the on-year anniversary of the vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
"SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced"
A hereditary kidney disorder in which fluid-filled sacs (cysts) form and grow on the kidneys, often caused when a single parent passes down a faulty gene. Over time the cysts can reduce kidney function and lead to serious health care needs, making it important to investors because it drives demand for diagnostic tests, drugs, medical devices and long-term care, and influences clinical trial activity and regulatory milestones.
JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company’s Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee’s acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards were granted pursuant to SCYNEXIS’ 2015 Inducement Award Plan, as amended, which was adopted by the Company’s Board of Directors in March 2015 under Rule 5635(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
The inducement awards consist of stock options to purchase 125,000 shares of the Company’s common stock at a per share exercise price of $0.93, the closing price per share of the Company’s common stock as reported by Nasdaq on April 30, 2026, and restricted stock units (“RSUs”) covering 20,000 shares of the Company’s common stock. The employee’s stock options have a vesting commencement date of April 13, 2026, vest over a four-year period, with 25% of the shares underlying the option vesting on the on-year anniversary of the vesting commencement date, and the remaining shares vest in equal monthly installments thereafter over 36 months, subject to the employee’s continued service with the Company. The employee’s RSUs have a vesting commencement date of June 15, 2026, and vest in three equal annual installments over a three-year period, subject to the employee’s continued service through each applicable vesting date.
About SCYNEXIS, Inc.
SCYNEXIS, Inc. (NASDAQ: SCYX) is dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com.
What equity awards did SCYNEXIS (SCYX) grant on April 30, 2026?
SCYNEXIS granted stock options for 125,000 shares and 20,000 RSUs as inducement awards. According to the company, the options carry a $0.93 exercise price, the Nasdaq closing price on April 30, 2026, and were approved under Nasdaq Rule 5635(c)(4).
What is the vesting schedule for the SCYNEXIS (SCYX) stock options awarded to the new VP?
The stock options vest over a four-year period with 25% vesting on the one-year anniversary. According to the company, the vesting commencement date is April 13, 2026, and remaining shares vest monthly over the following 36 months, subject to continued service.
When do the SCYNEXIS (SCYX) RSUs granted to the new VP begin vesting and over what period?
The RSUs have a vesting commencement date of June 15, 2026 and vest in three equal annual installments. According to the company, vesting is subject to the employee’s continued service through each applicable vesting date.
Under what plan and Nasdaq rule were the SCYNEXIS (SCYX) inducement awards granted?
The awards were granted under the company’s 2015 Inducement Award Plan pursuant to Nasdaq Listing Rule 5635(c)(4). According to the company, the inducement grants were approved as material inducements to the new hire’s acceptance of employment.
What exercise price was set for the SCYNEXIS (SCYX) options and how was it determined?
The exercise price for the options was set at $0.93 per share, equal to the Nasdaq closing price on April 30, 2026. According to the company, that closing price was used as the per-share exercise price for the inducement grant.
